

JC17 Rec'd PCT/PTO 16 APR 2001

PCT

Filed Via Certified Mail
Rec. No.: 7000 0600 0024 0744 4329
On: April 13, 2001

09/762283

By: Cheryl Schoenfeld
Cheryl Schoenfeld

Any fee due as a result of this paper, not covered by an enclosed check, may be charged on Deposit Acct. No. 08-1634.

Attorney Docket No. HERR 18.313

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Rosa PEREZ GOMARIZ, et al.

Serial No.: 09/762,283

Filed: February 5, 2001

Title: **METHOD FOR TREATING ENDOTOXIC SHOCK
AND INFLAMMATORY AND AUTOIMMUNE
DISEASES IN MAMMALS**

Examiner:

Art Unit:

April 13, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

S I R:

In order to comply with discretionary rules 37 CFR §§1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to issue a patent in the instant application.

As this Statement is being filed prior to issuance of a first Office Action, no fee is due.


As one document is written in a language other than English, an English language abstract is annexed hereto explaining the relevancy in accordance with 37 CFR §1.98(a)(3).

The present Information Disclosure Statement is being submitted in compliance with 37 CFR §1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104 (a) and 1.106 (b), and in the course of such search will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is respectfully solicited.


Any fee due with this paper, not fully covered by an enclosed check, may be charged on Deposit Account 08-1634.

Respectfully submitted,



Aaron B. Karas
Reg. No. 18,923

HELFGOTT & KARAS, P.C.
EMPIRE STATE BUILDING
60TH FLOOR
NEW YORK, NEW YORK 10118
(212) 643-5000
DOCKET NO. HERR 18.313



Please type a plus sign (+) → +

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

1449/PTO

U.S. Department of Commerce
Patent and Trademark Office

Application No. : 09/762,283

Filing Date : February 5, 2001

First Named Inventor : R.P. Gomariz, et al.

Group Art Unit :

Examiner Name :

Attorney Docket No. : HERR 18.313

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document	Kind Code if known ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Country	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns Lines Where Relevant Passages or Relevant Figures Appear
		WO 99/53944	WIPO		10/28/1999	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, country, where published, source.	Applicant check here if English language translation attached ⁶
		Advances in Neuroimmunology, Vol. 6, pp. 61-74, 1996, Elsevier Science, Ltd., D. Ganea, "Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs.	

Examiner Signature	Date Considered
-----------------------	--------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1⁶ if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.